Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
- 25 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 18 (6), 363-378
- https://doi.org/10.1038/s41571-020-00456-y
Abstract
As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described and the potential for extending their therapeutic benefit grows, optimizing the implementation of this therapeutic modality is imperative. The recognition and management of cytokine release syndrome (CRS) marked a milestone in this field; however, beyond the understanding gained in treating CRS, a host of additional toxicities and/or potential late effects of CAR T cell therapy warrant further investigation. A multicentre initiative involving experts in paediatric cell therapy, supportive care and/or study of late effects from cancer and haematopoietic stem cell transplantation was convened to facilitate the comprehensive study of extended CAR T cell-mediated toxicities and establish a framework for new systematic investigations of CAR T cell-related adverse events. Together, this group identified six key focus areas: extended monitoring of neurotoxicity and neurocognitive function, psychosocial considerations, infection and immune reconstitution, other end organ toxicities, evaluation of subsequent neoplasms, and strategies to optimize remission durability. Herein, we present the current understanding, gaps in knowledge and future directions of research addressing these CAR T cell-related outcomes. This systematic framework to study extended toxicities and optimization strategies will facilitate the translation of acquired experience and knowledge for optimal application of CAR T cell therapies.Keywords
This publication has 134 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromesHaematologica, 2010
- Pediatric Therapy-related Myelodysplastic Syndrome/Acute Myeloid LeukemiaJournal of Pediatric Hematology/Oncology, 2009
- Hemophagocytosis exacerbated by G‐CSF/GM‐CSF treatment in a patient with myelodysplasiaAmerican Journal of Hematology, 2004
- Ophthalmic manifestations of acute leukaemias: the ophthalmologist's roleEye, 2004
- ReviewNeurocognitive sequelae of childhood cancers and their treatmentPediatric Rehabilitation, 2004